TECH analyst estimates
Bio-Techne (TECH) analyst ratings, the average price target and its range, and every firm's latest call.
TECH analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | Bio-Techne downgraded to Equal Weight from Overweight at Wells Fargo | $73.00 |
| Jun 26, 2026 | Deutsche Bank | Deutsche Bank Downgrades Bio-Techne Corp. (TECH) to Hold | $73.00 |
| Jun 26, 2026 | Robert W. Baird | Bio-Techne price target raised to $73 from $49 at Baird | $73.00 |
| Jun 26, 2026 | Stephens | Bio-Techne downgraded to Equal Weight from Overweight at Stephens | $73.00 |
| Jun 25, 2026 | Leerink Partners | Bio-Techne downgraded to Market Perform from Outperform at Leerink | $73.00 |
| Jun 11, 2026 | Piper Sandler | Bio-Techne initiated with a Neutral at Piper Sandler | $65.00 |
| May 14, 2026 | RBC Capital | Bio-Techne resumed with an Outperform at RBC Capital | $62.00 |
| May 7, 2026 | Robert W. Baird | Bio-Techne price target lowered to $49 from $70 at Baird | $49.00 |
| May 7, 2026 | Stifel Nicolaus | Bio-Techne price target lowered to $50 from $65 at Stifel | $50.00 |
| May 7, 2026 | Evercore ISI | Bio-Techne price target lowered to $50 from $54 at Evercore ISI | $50.00 |
| Feb 5, 2026 | Robert W. Baird | Bio-Techne price target raised to $70 from $61 at Baird | $70.00 |
| Feb 5, 2026 | UBS | Bio-Techne price target raised to $79 from $70 at UBS | $79.00 |
| Feb 5, 2026 | Stifel Nicolaus | Bio-Techne price target raised to $65 from $60 at Stifel | $65.00 |
| Jan 5, 2026 | Evercore ISI | Bio-Techne downgraded to In Line from Outperform at Evercore ISI | $62.00 |
| Dec 12, 2025 | Deutsche Bank | Bio-Techne price target raised to $72 from $66 at Deutsche Bank | $72.00 |
- 13 firms rate TECH: 2 buy, 11 hold, 0 sell.
- The average price target is $65.78 from 9 analysts, from $50.00 to $73.00.
Updated 2026-11-02 17:51 UTC